[TABS_R id=3450] Interested in speaking at the workshop? Contact email@example.com.
Demand forecasting—the ability to project demand by role and project—is an important part of resource management. Companies conduct demand forecasting in several ways. Some have project managers enter demand by role for, say, 12 months. Others communicate standards to help drive consistency in how project managers estimate demand. Still, others create demand forecasting algorithms to[…]
In the Life Sciences industry, we’ve been managing projects since the birth of acetaminophen. Recent years have brought a demand for project managers to manage “more tightly.” Already aggressive timelines are being further accelerated. Pressure for speed and efficiency is at a record high. Everyone involved in project management is rolling up their sleeves to gain[…]
Regardless of how one looks at the current state of investigator meetings, there is no question there is room for improvement. Like any improvement initiative, the first question the sponsor needs to ask is, “How does this benefit the bottom line?” The value of an investigator meeting needs to be properly defined and evaluated. Any subsequent[…]
In previous blogs, I mentioned issues mentioned with regards to collecting feedback via surveys. However, I was able to collect a significant amount of data from attendees at various investigator meetings (21 in total, all Phase III studies). I used two different sets of standardized surveys throughout: internal (sponsor focused) and external (site focused). At the end of[…]
As mentioned in Part 1 of this blog series, 78% of respondents in the CenterWatch Monthly survey rated the overall usefulness of investigator meetings as “Good” or “Excellent.” But how does one define usefulness? To whom is the meeting useful and for what reason? According to one of the respondents, “The networking is, frankly, the only[…]
Nowadays, conducting a clinical study is more complicated than ever. Clinical studies have more complex protocols, new technologies, and increased regulatory scrutiny. It has made study execution more challenging. Regardless of the rise in difficulty, what matters is that a sponsor collects good, clean data that reflect how well its drug works. This increased difficulty raises[…]